Surveillance

ZE Government Solutions Announces Phase II SBIR Award from the Air Force to Develop Anomaly Detection on the Compressed Domain Interface

Retrieved on: 
Tuesday, June 20, 2023
Transfer, Air Force Research Laboratory, Small business, Semey, Swap, STTR, SBIR, Eye, ISR, Small Business Innovation Research, Risk, DAF, Air force, AFWERX, Department of the Air Force Police, Risk management, Reconnaissance, Surveillance, Power

The integrated solution, LSVS, combines ZEGS' A.I.-based object detection video analytics with a low SWaP camera to proactively identify, track and respond in real-time to threats or potential threats such as objects of interest, adversary UASs, projectiles, or ground intrusions.

Key Points: 
  • The integrated solution, LSVS, combines ZEGS' A.I.-based object detection video analytics with a low SWaP camera to proactively identify, track and respond in real-time to threats or potential threats such as objects of interest, adversary UASs, projectiles, or ground intrusions.
  • The backpack-sized solution will enable forces to gain critical situational awareness with a multitude of capabilities including persistent horizontal Intelligence, Surveillance, and Reconnaissance (ISR) and long range reconnaissance.
  • "There is always a risk when service members stop to set up camp or conduct other activities," said Mike Lahiff, CEO and co-founder of ZeroEyes, parent company of ZEGS.
  • "Now they will be able to deploy our SWaP LSVS in minutes to help gain situational awareness and keep an eye out for threats while they concentrate on the job at hand."

Global Airborne Intelligence Surveillance and Reconnaissance (ISR) Strategic Business Report 2023: Increasing Demand for Unmanned Applications of ISR Driving Growth

Retrieved on: 
Monday, June 12, 2023
Real, Intelligence, Unemployment, Race, Crew, Virus, Safety, COVID-19, Developed country, South African Unemployed Peoples' Movement, USD, Fatality, Development, Department of Defence, GDP, Atmosphere of Earth, Drone, Growth, Communication, Consumer, Automatic, Navigation, IMF, Video game, Semiconductor, Arms industry, Revenue, Surveillance, Terrorism

The Race Between the Virus & Vaccines Intensifies.

Key Points: 
  • The Race Between the Virus & Vaccines Intensifies.
  • Amidst this Chaotic Battle, Where is the World Economy Headed in 2021?
  • With IMF's Upward Revision of Global GDP Forecasts for 2021, Most Companies Are Bullish about an Economic Comeback Despite a Continuing Pandemic
    A Strong Yet Exceedingly Patchy & Uncertain Recovery Shaped by New Variants Comes Into Play: World Economic Growth Projections (Real GDP, Annual % Change) for 2020 through 2022
    Easing Unemployment Levels in 2021 Although Moderate Will Infuse Hope for Industries Reliant on Consumer Discretionary Incomes: Global Number of Unemployed People (In Million) for Years 2019, 2020, 2021, and 2022
    Infection Spread Disrupts Military Personnel Training & Troop Deployment: Cumulative Number of COVID-19 Cases Across the Defense Department in the U.S. in May, June, September & November 2020
    Global Airborne Intelligence Surveillance and Reconnaissance Market by Solution (2021 & 2027): Percentage Breakdown of Revenues for Systems, Solutions, and Service
    Global Airborne Intelligence Surveillance and Reconnaissance Market by Platform Type (2021 & 2027): Percentage Breakdown of Revenues for Sea, Air, Space, and Land
    Global Airborne Intelligence Surveillance and Reconnaissance Market by Application (2021 & 2027): Percentage Breakdown of Revenues for Unmanned, and Manned
    Developed Regions Account for Major Share of World Airborne Intelligence Surveillance and Reconnaissance Market: Percentage Breakdown of Revenues for Developed and Developing Regions (2021 & 2027)
    Global Market for Airborne Intelligence Surveillance and Reconnaissance - Geographic Regions Ranked by % CAGR (Revenues) for 2020-2027: China, Asia-Pacific, Latin America, Middle East, Africa, Canada, USA, Europe, and Japan
    Why Improving the ISR Systems is Necessary for the US?
  • Global Market for Military Drones (In US$ Billion) for the Years 2018, 2020, 2022 and 2024
    World High Altitude Platforms Market by Payload (2021): Percentage Breakdown of Revenues for Communication, Surveillance, Navigation, and EO/IR Systems
    Integration of Automatic Dependent Surveillance Broadcast (ADS-B) into Drones: A Move to Enhance Safety
    Defense Spending Levels Influence Growth in Airborne Intelligence, Surveillance, and Reconnaissance Systems Market
    Top Countries with Military Spending in USD Billion: 2019 and 2020
    Military Expenditure as a % of GDP in Select Countries: 2020
    Continued Threat of Terrorism Drives the Focus on Surveillance as Counterterrorism Response: Global Number of Fatalities Due to Terrorist Attacks: 2012-2019
    Global Soldier Modernization Market Size (in US$ Billion) for 2018, 2021, 2024 & 2027

GRAIL Presents Real-World Experience With The Galleri® Multi-Cancer Early Detection Test At 2023 ASCO Annual Meeting

Retrieved on: 
Saturday, June 3, 2023
Oncology, Medical Supplies, Health, Health Technology, General Health, Research, Science, Lymphoma, Pancreatic cancer, CSD, Ovary, CSO, Pancreas, Cancer, Esophagus, Head, Breast, Multimedia, Risk, Prostate, Neck, Uterus, Lung, II, ASCO, Incidence, Sarcoma, DO, Lymphoid leukemia, American Society of Clinical Oncology, Adventist Health, MD, Patient, Surveillance, Annual general meeting, Kidney, Systematic, SEER, Diagnosis, Society, Medical imaging, Epidemiology, GRAIL, GRAIL (company)

The findings were presented during a poster discussion session at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting.

Key Points: 
  • The findings were presented during a poster discussion session at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting.
  • As part of the clinical surveillance program, GRAIL follows CSD results by contacting ordering providers 3 months or more after the Galleri test result to collect cancer outcomes.
  • One of the patients for whom Galleri detected a lethal cancer early is Roger Royse, who took the test at age 62.
  • We continue to see an average cancer signal detection rate of 1%, which as expected increases with age.

Castle Biosciences to Share New Data on DecisionDx®-Melanoma and DecisionDx®-UM at the 2023 ASCO Annual Meeting

Retrieved on: 
Saturday, June 3, 2023
Research, Genetics, Clinical Trials, Biotechnology, Health, Optical, Other Science, Science, Oncology, Abstract, Uveal melanoma, ASCO, National Cancer Institute, American Society of Clinical Oncology, Patient, Surveillance, Annual general meeting, SEER, NCI, Society, Medical imaging, Epidemiology

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that new data on DecisionDx®-Melanoma and DecisionDx®-UM will be shared during the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place June 2-6.

Key Points: 
  • Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that new data on DecisionDx®-Melanoma and DecisionDx®-UM will be shared during the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place June 2-6.
  • DecisionDx-Melanoma is the Company’s genomic risk-stratification test for patients with cutaneous melanoma, and DecisionDx-UM is the standard of care in the management of newly diagnosed uveal melanoma in the majority of ocular oncology practices in the United States.
  • Details regarding Castle’s accepted abstracts are as follows:
    Abstract #6601: Integrating the 31-gene expression profile test into clinical decision-making to guide risk-aligned care decisions for patients with stage I-III cutaneous melanoma: NCI-SEER Analysis.
  • First Author: David Hyams, M.D., F.A.C.S., director of Desert Surgical Oncology in Rancho Mirage, California
    Abstract #e21574: Long-term outcomes in a population-based cohort of 2,967 uveal melanoma patients clinically tested with the 15-gene expression profile: A collaborative study with the National Cancer Institute (NCI) Surveillance, Epidemiology, and End Results (SEER) Program Registries.

Exact Sciences Presents New Long-Term Patient Outcomes in Multi-Cancer Early Detection and Breast Cancer Recurrence Testing at ASCO® 2023

Retrieved on: 
Friday, May 26, 2023
IDC, Survivor, Abstract, American Society of Clinical Oncology, CMS, Cancer, Oncotype (Denmark), Exact sciences, ASCO, Incidence, Medicine, MD, Patient, Colorectal cancer, Risk, Lymph, Blood, Surveillance, Annual general meeting, RS, SEER, Science, Mortality, Exact Sciences (company), Recurrence, Society, Invasive carcinoma of no special type, Breast cancer, Disease, ILC, Medical imaging, Liquor, Pharmaceutical industry, Epidemiology

"These first-ever, long-term MCED follow-up data confirm Exact Sciences' approach to detecting multiple cancers at earlier stages of disease, and show that early detection enables successful treatment and long-term freedom from cancer in patients," said Tom Beer, MD, Chief Medical Officer, Multi-Cancer Early Detection, Exact Sciences.

Key Points: 
  • "These first-ever, long-term MCED follow-up data confirm Exact Sciences' approach to detecting multiple cancers at earlier stages of disease, and show that early detection enables successful treatment and long-term freedom from cancer in patients," said Tom Beer, MD, Chief Medical Officer, Multi-Cancer Early Detection, Exact Sciences.
  • In addition, Exact Sciences will present a new, long-term Surveillance, Epidemiology, and End Results (SEER) analysis showing that the Oncotype DX Breast Recurrence Score® test is prognostic for breast cancer-specific mortality (BCSM) in patients with invasive ductal carcinoma (IDC) and invasive lobular breast cancer (ILC).
  • The Oncotype DX Breast Recurrence Score test is a prognostic genomic test designed to predict the likelihood of disease recurrence and chemotherapy benefit for patients with early-stage breast cancer, which Exact Sciences clinically validated in the TAILORx and RxPONDER trials.
  • Abstract #e22508 (E-pub): A flexible quantitative framework to assess the potential contribution of early cancer detection to improved cancer survival.

EQS-News: Mainz Biomed Partners with Microba Life Sciences for the Development of PancAlert

Retrieved on: 
Wednesday, May 10, 2023
Survival rate, Pancreatic cancer, Database, MAP, PMID, Therapy, CRC, Epidemiology, Survival, Pancreas, Cancer, ASX, Gene expression, Biomarker, Mortality, Messenger, National Cancer Institute, MCP, Colorectal cancer, SEER, Diagnosis, Disease, Pharmaceutical industry, Vaccine, Surveillance, Incidence

BERKELEY, US and MAINZ, Germany – [May 10, 2023] -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today a research collaboration with Microba Life Sciences (ASX: MAP) (“Microba”), a precision microbiome company leveraging a world-leading technology platform for measuring the human gut microbiome to discover and develop novel therapeutics for major diseases. As part of the agreement, Microba and Mainz Biomed will conduct a pilot research project utilizing Microba’s proprietary metagenomic sequencing technology and bioinformatic tools to potentially discover novel microbiome biomarkers for pancreatic cancer detection.

Key Points: 
  • BERKELEY, US and MAINZ, Germany – [May 10, 2023] -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today a research collaboration with Microba Life Sciences (ASX: MAP) (“Microba”), a precision microbiome company leveraging a world-leading technology platform for measuring the human gut microbiome to discover and develop novel therapeutics for major diseases.
  • As part of the agreement, Microba and Mainz Biomed will conduct a pilot research project utilizing Microba’s proprietary metagenomic sequencing technology and bioinformatic tools to potentially discover novel microbiome biomarkers for pancreatic cancer detection.
  • Pancreatic cancer is a malignant neoplasm of the pancreas with one of the highest mortality rates of all major cancers.
  • Results from eAArly DETECT are expected in mid-2023 and Mainz anticipates enrollment in ReconAAsense to commence in the second half of 2023.

Mainz Biomed Partners with Microba Life Sciences for the Development of PancAlert

Retrieved on: 
Wednesday, May 10, 2023
Survival rate, Pancreatic cancer, Database, MAP, PMID, Therapy, CRC, Epidemiology, Survival, Pancreas, Cancer, ASX, Gene expression, Biomarker, Mortality, Messenger, National Cancer Institute, MCP, Colorectal cancer, SEER, Diagnosis, Disease, Pharmaceutical industry, Medical imaging, Vaccine, Surveillance, Incidence

As part of the agreement, Microba and Mainz Biomed will conduct a pilot research project utilizing Microba’s proprietary metagenomic sequencing technology and bioinformatic tools to potentially discover novel microbiome biomarkers for pancreatic cancer detection.

Key Points: 
  • As part of the agreement, Microba and Mainz Biomed will conduct a pilot research project utilizing Microba’s proprietary metagenomic sequencing technology and bioinformatic tools to potentially discover novel microbiome biomarkers for pancreatic cancer detection.
  • Pancreatic cancer is a malignant neoplasm of the pancreas with one of the highest mortality rates of all major cancers.
  • “We are excited by the opportunity to collaborate with Microba as PancAlert is being developed for early-stage disease detection with the goal of being a first-in-class screening test for this deadly form of cancer,” commented Guido Baechler, Chief Executive Officer of Mainz Biomed.
  • Results from eAArly DETECT are expected in mid-2023 and Mainz anticipates enrollment in ReconAAsense to commence in the second half of 2023.

Albedo Wins U.S. Air Force Contract for Nighttime Thermal Infrared Imaging

Retrieved on: 
Thursday, April 27, 2023
Other Defense, Contracts, Construction & Property, Aerospace, Data Management, Satellite, Manufacturing, Government Technology, Photography, Technology, Audio, Video, Defense, Military, Other Technology, Software, Other Construction & Property, USAF, SBIR, NASIC, GSD, Unitary state, Multimedia, United States Space Force, Government, USSF, National Air and Space Intelligence Center, TIR, Direct, Radar, Traction, Air force, The, Ground sample distance, AFWERX, Department of the Air Force Office of Special Investigations, Television, Surveying, Intelligence, Surveillance

The Direct to Phase 2 (D2P2) SBIR contract through AFWERX, the innovation arm for the Department of the Air Force, will test and evaluate Albedo’s commercial leading, 2 meter GSD (Ground Sample Distance) Thermal Infrared (TIR) imaging for nighttime conditions for the U.S. Government.

Key Points: 
  • The Direct to Phase 2 (D2P2) SBIR contract through AFWERX, the innovation arm for the Department of the Air Force, will test and evaluate Albedo’s commercial leading, 2 meter GSD (Ground Sample Distance) Thermal Infrared (TIR) imaging for nighttime conditions for the U.S. Government.
  • (Graphic: Business Wire)
    Albedo will natively co-collect the highest-resolution commercial satellite imagery available in the visible (10 cm GSD) and thermal infrared (2 m GSD) spectrums.
  • This is Albedo’s second D2P2 contract award through AFWERX in under a year, increasing the company’s government contract total to $2.5 million.
  • “High-resolution thermal infrared will provide a new commercial remote sensing solution for the U.S. Space Force.”
    Under this contract, Albedo will characterize its night-time TIR imaging capabilities.

Nasdaq Reports First Quarter 2023 Results; Diverse Product Platform Delivers Broad-Based Growth

Retrieved on: 
Wednesday, April 19, 2023
Software as a service, Amazon Web Services, Share repurchase, Google Marketing Platform, Tier 2, Intelligence, GAAP, ACH, Movement, Verafin, AML, AUM, Acquisition, Investment, Nature, FX, ARR, Surveillance, Initial public offering, Case management, CFO, Growth, Fraud, Health, AWS, Chair, Video game, Management, Pharmaceutical industry, Bank, Cryptocurrency, Security (finance), Index

Adena Friedman, Chair and CEO said, “Nasdaq delivered a solid financial performance during the first quarter of 2023, driven by momentum across our divisions.

Key Points: 
  • Adena Friedman, Chair and CEO said, “Nasdaq delivered a solid financial performance during the first quarter of 2023, driven by momentum across our divisions.
  • Solutions businesses revenues were $646 million in the first quarter of 2023, an increase of $23 million, or 4%.
  • Trading Services net revenues were $267 million in the first quarter of 2023, an increase of $3 million, or 1%.
  • In the first quarter of 2023, Nasdaq led all exchanges during the period in total volume traded for multiply-listed equity options.

CareDx Showcases Leadership with Over 55 Oral Presentations and Posters at the 43rd Annual Meeting & Scientific Sessions of the International Society for Heart and Lung Transplantation

Retrieved on: 
Wednesday, April 19, 2023
Health, Surgery, Clinical Trials, Research, Cardiology, Science, Columbia University, University of Southern California, Heart, Abstract, University, FAST, Stanford University, University of Maryland, College Park, University of Maryland Medical Center, Molecular diagnostics, Vanderbilt University, Stanford University Medical Center, Assistant, Maryland School, Patient, Risk, Master of Science, University of Maryland School of Medicine, Medicine, FCCP, Hospital, CDT, Role, MPH, International Society for Heart and Lung Transplantation, International Society, University of Virginia, Caregiver, Heart transplantation, Dentistry, Food delivery, Lung transplantation, Brigham, MD, Surveillance

Challenging Cases in Post-Cardiac Transplant Care: The Role of Molecular Diagnostics in Surveillance, April 20, 11:30am, CDT.

Key Points: 
  • Challenging Cases in Post-Cardiac Transplant Care: The Role of Molecular Diagnostics in Surveillance, April 20, 11:30am, CDT.
  • Moderated by Eugene DePasquale, MD, University of Southern California and Jeremy Kobulnik, MD, CareDx.
  • Just Breathe - Facing Clinical Challenges in Lung Transplantation, April 21, 11:30am, CDT.
  • Speakers include Hannah Mannem, MD, University of Virginia; Nirmal Sharma, MD, Brigham and Women’s Hospital; and Anil Trindade, MD, Vanderbilt University.